Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR. Schöffski P, et al. Among authors: hanauske ar. Ann Oncol. 1999 Jan;10(1):119-22. doi: 10.1023/a:1008360323986. Ann Oncol. 1999. PMID: 10076732 Free article. Clinical Trial.
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N, Aamdal S, Awada A, Calvert H, Fumoleau P, Sorio R, Punt C, Verweij J, van Oosterom A, Morant R, Wanders J, Hanauske AR. Pavlidis N, et al. Among authors: hanauske ar. Cancer Chemother Pharmacol. 2000;46(2):167-71. doi: 10.1007/s002800000134. Cancer Chemother Pharmacol. 2000. PMID: 10972487 Clinical Trial.
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Schellens JH, Dombernowsky P, Cassidy J, Epelbaum R, Dirix L, Cox EH, Wanders J, Calabresi F, Paridaens R, Monfardini S, Wolff J, Loos WJ, Verweij J, Pavlidis N, Hanauske AR; EORTC Early Clinical Studies Group. Schellens JH, et al. Among authors: hanauske ar. Anticancer Drugs. 2001 Aug;12(7):583-90. doi: 10.1097/00001813-200108000-00004. Anticancer Drugs. 2001. PMID: 11487714 Clinical Trial.
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Eskens FA, Greim GA, van Zuylen C, Wolff I, Denis LJ, Planting AS, Muskiet FA, Wanders J, Barbet NC, Choi L, Capdeville R, Verweij J, Hanauske AR, Bruntsch U. Eskens FA, et al. Among authors: hanauske ar. Clin Cancer Res. 2000 May;6(5):1736-43. Clin Cancer Res. 2000. PMID: 10815892 Clinical Trial.
Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, Pacciarini MA, Domenigoni L, van Weissenbruch F, Pianezzola E, de Vries EG. Bakker M, et al. Among authors: hanauske ar. Br J Cancer. 1998;77(1):139-46. doi: 10.1038/bjc.1998.22. Br J Cancer. 1998. PMID: 9459159 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M; European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Eskens FA, et al. Among authors: hanauske ar. J Clin Oncol. 2001 Feb 15;19(4):1167-75. doi: 10.1200/JCO.2001.19.4.1167. J Clin Oncol. 2001. PMID: 11181683 Clinical Trial.
119 results